CG ONCOLOGY INC (CGON) Stock Price, Quote, News and Overview
NASDAQ:CGON - Nasdaq - US1569441009 - Common Stock - Currency: USD
CGON Quote, Performance and Key Statistics
24.85
+0.5 (+2.05%)
The current stock price of CGON is 24.85 USD. In the past month the price decreased by -7%. In the past year, price decreased by -26.11%.
CGON Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.7 | 349.84B | ||
| AMGN | AMGEN INC | 13.22 | 154.98B | ||
| GILD | GILEAD SCIENCES INC | 15.43 | 148.54B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.64 | 94.13B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 60.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 57.23B | ||
| ARGX | ARGENX SE - ADR | 71.39 | 40.50B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.5 | 31.19B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.84B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.28B | ||
| INSM | INSMED INC | N/A | 20.78B | ||
| NTRA | NATERA INC | N/A | 20.75B |
Related stock screener links
About CGON
Company Profile
CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. The company is headquartered in Irvine, California and currently employs 113 full-time employees. The company went IPO on 2024-01-25. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
Company Info
CG ONCOLOGY INC
400 Spectrum Center Drive, Suite 2040
Irvine CALIFORNIA US
Employees: 113
Phone: 19492886298
CG ONCOLOGY INC / CGON FAQ
What is the stock price of CG ONCOLOGY INC today?
The current stock price of CGON is 24.85 USD. The price increased by 2.05% in the last trading session.
What is the ticker symbol for CG ONCOLOGY INC stock?
The exchange symbol of CG ONCOLOGY INC is CGON and it is listed on the Nasdaq exchange.
On which exchange is CGON stock listed?
CGON stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CG ONCOLOGY INC stock?
17 analysts have analysed CGON and the average price target is 59.73 USD. This implies a price increase of 140.35% is expected in the next year compared to the current price of 24.85. Check the CG ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CG ONCOLOGY INC worth?
CG ONCOLOGY INC (CGON) has a market capitalization of 1.89B USD. This makes CGON a Small Cap stock.
How many employees does CG ONCOLOGY INC have?
CG ONCOLOGY INC (CGON) currently has 113 employees.
What are the support and resistance levels for CG ONCOLOGY INC (CGON) stock?
CG ONCOLOGY INC (CGON) has a support level at 24.35 and a resistance level at 25.9. Check the full technical report for a detailed analysis of CGON support and resistance levels.
Is CG ONCOLOGY INC (CGON) expected to grow?
The Revenue of CG ONCOLOGY INC (CGON) is expected to decline by -58.84% in the next year. Check the estimates tab for more information on the CGON EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CG ONCOLOGY INC (CGON) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CGON, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CGON, evaluating the profitability, health, valuation and growth aspects
- CG ONCOLOGY INC (CGON) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CG ONCOLOGY INC (CGON) Sales and EPS estimates to see what analysts future expectations are.
- CG ONCOLOGY INC (CGON) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CG ONCOLOGY INC (CGON) Insider and Institutional Ownership to learn about the owners and their transactions.
- CG ONCOLOGY INC (CGON) Stock Chart to make your own analysis
- CG ONCOLOGY INC (CGON) Latest news and press-releases to stay up to date.
Does CG ONCOLOGY INC (CGON) stock pay dividends?
CGON does not pay a dividend.
What is the Price/Earnings (PE) ratio of CG ONCOLOGY INC (CGON)?
CG ONCOLOGY INC (CGON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.51).
What is the Short Interest ratio of CG ONCOLOGY INC (CGON) stock?
The outstanding short interest for CG ONCOLOGY INC (CGON) is 15.62% of its float. Check the ownership tab for more information on the CGON short interest.
CGON Technical Analysis
CGON Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CGON. No worries on liquidiy or solvency for CGON as it has an excellent financial health rating, but there are worries on the profitability.
CGON Financial Highlights
Over the last trailing twelve months CGON reported a non-GAAP Earnings per Share(EPS) of -1.51. The EPS decreased by -31.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.5% | ||
| ROE | -14.98% | ||
| Debt/Equity | 0 |
CGON Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 81% to CGON. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of -32.01% and a revenue growth -58.84% for CGON